Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2025

Rhea-AI Summary

Pharma-Bio Serv (OTCQB:PBSV), a consulting firm serving pharmaceutical and related industries, reported its financial results for Q2 2025. The company achieved revenues of $2.4 million for Q2 and $4.9 million for H1 2025, showing modest growth from $2.3 million and $4.8 million in the respective periods of 2024. Net income for both Q2 and H1 2025 was approximately $0.1 million each, marking significant improvements of $0.3 million and $0.6 million compared to the same periods last year. CEO Mr. Sanchez attributed the improved performance to the company's strategic focus on high-margin projects, expressing optimism about future growth potential.

Positive

• Net income improved significantly by $0.3M in Q2 and $0.6M in H1 2025 compared to 2024
• Revenue showed growth to $2.4M in Q2 2025 from $2.3M in Q2 2024
• Strategic focus on high-margin projects is yielding positive results

Negative

• Revenue growth remains modest at approximately 4.3% year-over-year
• Absolute net income of $0.1M remains relatively small despite improvements

DORADO, PR / ACCESS Newswire / June 16, 2025 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the three and six months ended April 30, 2025 were approximately $2.4 million and $4.9, million, respectively. Revenues for the three and six months ended April 30, 2024 were approximately $2.3 million and $4.8 million, respectively. Net income for the three and six months ended April 30, 2025 was approximately $0.1 million for each period, an earnings increase of approximately $0.3 million and $0.6 million when compared to the same periods last year, respectively.

"The results of this second quarter demonstrate our efforts to concentrate on high margin yielding projects. We believe these efforts position us well for future growth," stated Mr. Sanchez, Chief Executive Officer of the Company.

About Pharma-Bio Serv, Inc.
Pharma-Bio Serv services the Puerto Rico, United States, Europe and Latin America markets. Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance consulting related services. The Company's global team includes leading engineering and life science professionals, quality assurance managers and directors.

Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Pharma-Bio Serv. Forward-looking statements are based on the expectations, estimates, or projections of management as of the date of this earnings announcement. Although Pharma-Bio Serv's management believes these expectations, estimates, or projections to be reasonable as of the date of this earnings announcement, forward-looking statements are inherently subject to significant business risks, economic uncertainties, and competitive uncertainties, and other factors, which could cause its actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause Pharma-Bio Serv's actual results or performance to differ materially from the forward-looking statements include those set forth in the "Risk Factors" section of Pharma-Bio Serv's Annual Report on Form 10-K for the year ended October 31, 2024, and in its other filings with the Securities and Exchange Commission, which filings are available at www.sec.gov. Pharma-Bio Serv disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.

Company Contact:
Pedro J. Lasanta
Chief Financial Officer
787 278 2709

SOURCE: Pharma-Bio Serv Inc.

View the original press release on ACCESS Newswire

FAQ

What were Pharma-Bio Serv's (PBSV) Q2 2025 earnings?

Pharma-Bio Serv reported net income of $0.1 million for Q2 2025, an improvement of $0.3 million compared to Q2 2024.

How much revenue did PBSV generate in Q2 2025?

PBSV generated revenues of $2.4 million in Q2 2025, up from $2.3 million in Q2 2024.

What is Pharma-Bio Serv's business focus?

Pharma-Bio Serv is a consulting firm providing compliance, project management, and technology transfer support services to pharmaceutical, biotechnology, chemical, medical device, cosmetic, food, and allied products industries.

How did PBSV's first half 2025 performance compare to 2024?

PBSV's H1 2025 revenue was $4.9 million versus $4.8 million in H1 2024, with net income improving by $0.6 million year-over-year.

What is PBSV's strategy for growth according to management?

According to CEO Mr. Sanchez, the company is focusing on high margin yielding projects to position itself for future growth.